Cargando…
Increased bleeding risk associated with the use of recombinant human activated protein C in patients with advanced liver disease
Autores principales: | Keene, Adam, Kawano, Thomas, Anees, Syed, Chen, Julie |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374633/ https://www.ncbi.nlm.nih.gov/pubmed/18304374 http://dx.doi.org/10.1186/cc6774 |
Ejemplares similares
-
Recombinant factor VIIa for variceal bleeding in liver cirrhosis: still only a hope
por: Qi, Xingshun, et al.
Publicado: (2017) -
Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia
por: ALMAGRO, D, et al.
Publicado: (2011) -
Bleeding Risks Associated With Herbal Medicine in Children
por: Ghauri, Abdul-Jabbar, et al.
Publicado: (2014) -
Use of recombinant factor VIIa in orthotopic liver transplant
por: Bhatia, Pradeep
Publicado: (2011) -
Emergency laparoscopy-treated spontaneous bleeding and cystobiliary communication of multiple liver cysts
por: Yang, Xianwei, et al.
Publicado: (2020)